Bank of Montreal Can Sells 244 Shares of LivaNova PLC (NASDAQ:LIVN)

Bank of Montreal Can reduced its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 0.4% during the third quarter, Holdings Channel reports. The institutional investor owned 63,646 shares of the company’s stock after selling 244 shares during the quarter. Bank of Montreal Can’s holdings in LivaNova were worth $3,343,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LIVN. Driehaus Capital Management LLC grew its stake in shares of LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after purchasing an additional 213,749 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of LivaNova by 48.5% in the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after purchasing an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC bought a new stake in shares of LivaNova in the second quarter worth about $16,614,000. Price T Rowe Associates Inc. MD grew its stake in shares of LivaNova by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,980 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new stake in shares of LivaNova in the second quarter worth about $1,103,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on LIVN shares. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Mizuho lowered their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Price Performance

LIVN stock opened at $51.19 on Thursday. The firm has a 50 day moving average price of $52.28 and a 200-day moving average price of $51.95. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 121.88 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.